Joshua Brody

Joshua Brody

Hematologist, Medical Oncologist

Lymphoma

Icahn School of Medicine at Mount Sinai

Location USA, New York

Linkedin

X

Dr. Joshua Brody is a hematologist-oncologist and translational cancer immunologist specializing in lymphoma, with a particular focus on developing novel immunotherapy approaches. He currently serves as Director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center, a NCI-Designated Comprehensive Cancer Center, and is a Professor of Medicine (Hematology and Medical Oncology), Immunology and Immunotherapy, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, as well as a faculty member of the Icahn Genomics Institute. Dr. Brody pioneered the concept of in situ vaccination — an approach that induces anti-tumor immunity directly at the tumor site and can drive regression of tumors throughout the body — and has made landmark contributions to CAR-T cell biology, cancer vaccine development, and combination immunotherapy strategies for treatment-resistant lymphomas.

Current Positions

  • Director, Lymphoma Immunotherapy Program, Mount Sinai Tisch Cancer Center, New York, NY
  • Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
  • Professor of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai
  • Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai
  • Faculty Member, Icahn Genomics Institute, Mount Sinai

Education

  • BA, Harvard University
  • MD, State University of New York at Stony Brook School of Medicine
  • Residency, Internal Medicine, Yale New Haven Hospital
  • Fellowship, Medical Oncology, Stanford University School of Medicine

Professional Experience

  • Faculty Member, Mount Sinai Tisch Cancer Center, 2011–present
  • Director, Lymphoma Immunotherapy Program, Mount Sinai, 2011–present
  • Founder and Principal Investigator, Brody Cancer Immunotherapy Lab, Mount Sinai — translational laboratory investigating basic and applied tumor immunology for the development of novel therapies in lymphoma, breast cancer, and head and neck cancer

Research Activity

  • In situ vaccination: Pioneered a therapeutic vaccine approach that induces anti-tumor immunity directly at the tumor site, capable of driving systemic regression of tumors throughout the body; this work has led to multiple clinical trials and publications in Nature Medicine and Cancer Discovery
  • CAR-T cell therapy and resistance: Discovered a novel approach to overcome a common tumor escape mechanism — antigen loss — that allows tumors to evade CAR-T and bispecific antibody therapies; demonstrated a critical role for Fas-mediated bystander tumor killing in T-cell immunotherapy (Cancer Discovery, 2021)
    Immunotherapy combined with stem cell transplantation: Developed strategies to enhance the potency of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation
  • Cancer vaccines: Co-authored a landmark review on cancer vaccines as the next immunotherapy frontier (Nature Cancer, 2022) and a major review in The Lancet (2025); active research in mRNA vaccine platforms, dendritic cell activation, and neoantigen-based approaches
  • Bispecific antibodies and immune checkpoint inhibitors: Active investigator in clinical trials of epcoritamab, glofitamab, nivolumab, and brentuximab vedotin combinations for relapsed/refractory aggressive B-cell and T-cell lymphomas
  • STING agonists and intratumoral immunotherapy: Co-author on SITC recommendations for intratumoral immunotherapy clinical trials; investigator in Phase I/II studies of STING agonists in solid tumors and lymphomas
  • Tumor microenvironment: Research on macrophage-T cell crosstalk, trogocytosis, CAR-T cell expansion, and adaptive resistance mechanisms

Research Funding:

  • National Institutes of Health (NIH)
  • Cancer Research Institute
  • Damon Runyon Cancer Research Foundation
  • Lymphoma Research Foundation
  • NCI Howard Temin Pathway to Independence Award (K99/R00)

Honors and Awards

  • Society for Immunotherapy of Cancer Presidential Award (SITC 26th Annual Meeting), 2011
  • SCL Award for Top Abstract, International Conference on Malignant Lymphoma, Swiss Cancer League, 2011
  • ASCO Merit Award for Top 100 Abstracts, American Society of Clinical Oncology Annual Meeting, 2011
  • Howard Temin Pathway to Independence Award in Cancer Research (K99/R00), NCI, 2009
  • Outstanding Recent Graduate, SUNY Stony Brook School of Medicine, 2009
  • ASCO Bradley Stuart Beller Foundation Fellowship Merit Award for Best Abstract, 2008
  • William Guy Forbeck Scholar Award, William Guy Forbeck Research Foundation, 2008
  • MCLC Featured Researcher, Mantle Cell Lymphoma Consortium, 2008

Memberships / Affiliations

  • Society for Immunotherapy of Cancer (SITC)
  • Alliance for Clinical Trials in Oncology
  • American Society of Clinical Oncology (ASCO)
  • American Association for Cancer Research (AACR)

Industry Consulting Relationships (2025–2026): Bristol-Myers Squibb, Genentech, Janssen Pharmaceuticals, Merck & Co., Seattle Genetics, Acerta Pharma, Kite-Gilead

Areas of Specialization

  • Lymphoma immunotherapy (non-Hodgkin lymphoma, Hodgkin lymphoma, DLBCL, mantle cell lymphoma, follicular lymphoma, T-cell lymphoma)
  • In situ vaccination and therapeutic cancer vaccines
  • CAR-T cell therapy and resistance mechanisms
  • Bispecific antibody therapies
  • Tumor microenvironment and immune evasion
  • Intratumoral immunotherapy
  • Immune checkpoint inhibitors in lymphoma
  • Dendritic cell biology and mRNA vaccine platforms
  • Combination immunotherapy with stem cell transplantation
  • Translational oncology and biomarker discovery

Publications

Dr. Brody has authored and co-authored more than 107 publications, including original research articles, review articles, clinical trial reports, book chapters, and commentaries in journals including Nature Medicine, Cancer Discovery, The Lancet, Nature Cancer, Nature Communications, Journal of Clinical Investigation, Blood, Cancer Cell, and Journal for ImmunoTherapy of Cancer.

Select Recent Publications:

Mateus-Tique J, Lakshmi A, Singh B, Iyer R, Sánchez-Paulete AR, Falcomatà C, Lin M, Pantsulaia G, Tepper A, Nguyen T, Amabile A, Mollaoglu G, Pia L, Chhamalwan D, Le Berichel J, Potak H, Colonna M, Baccarini A, Brody J, Merad M, Brown BD. “Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth.” Cancer Cell 44(3):534–550.e11, March 2026.

Pail O, Lin MJ, Anagnostou T, Brown BD, Brody JD. “Cancer vaccines and the future of immunotherapy.” The Lancet 406(10499):189–202, July 2025.

Marks A, Siu S, Bianchini F, Wang C, Lakshmi A, Phelan M, Zhu A, Moon C, Morla-Folch J, Teunissen AJP, Amabile A, Baccarini A, Merad M, Brody JD, Dong Y, Brown BD. “mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.” Nature Biotechnology, 2026. In press.

Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, et al. “Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.” Clinical Cancer Research 31(16):3400–3411, August 2025.

Morris ZS, Demaria S, Monjazeb AM, Formenti SC, Weichselbaum RR, Welsh J, Brody JD, et al. “Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.” The Lancet Oncology 26(3):e152–e170, March 2025.

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Brooks TR, Zabor EC, Bedelu YB, Brody J, et al. Blood 146(18):2177–2188, October 2025.

Aleman A, Van Oekelen O, Melnekoff DT, Odak I, Brody JD, et al. “Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.” New England Journal of Medicine 393(8):823–825, August 2025.

Hou X, Wang C, Zhong Y, Wang L, Kang DD, Lubitz G, Marron TU, Brown BD, Merad M, Brody JD, Dong Y, et al. “Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation.” Journal of Controlled Release 382:113684, June 2025.

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC. Blood 145(15):1621–1631, April 2025.

Fiore D, Cappelli LV, Brody J, et al. “A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.” Cell Reports Medicine 6(4):102029, April 2025.

Crombie JL, Graff T, Falchi L, Karimi YH, Brody J, Abramson JS, et al. “Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.” Blood 143(16):1565–1575, April 2024.

Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, et al. “Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials.” Journal for ImmunoTherapy of Cancer 12(4):e008378, April 2024.

Aminov S, Giricz O, Melnekoff DT, Brody J, et al. “Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.” Journal of Clinical Investigation 134(8):e175199, April 2024.

Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. “Cancer vaccines: the next immunotherapy frontier.” Nature Cancer 3(8):911–926, August 2022.

Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L, Merad M, Brown BD, García-Sastre A, Brody JD. “Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.” Nature Communications 13(1):7149, December 2022.

Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, Scholler N, Bot A, Rossi JM, Baccarini A, Merad M, Brown BD, Brody JD. “A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy.” Cancer Discovery 11(3):599–613, March 2021.

Van Oekelen O, Aleman A, Brody JD, Merad M, Jagannath S, Parekh S, et al. “Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.” Nature Medicine 27(12):2099–2103, December 2021.

All information is sourced from publicly available materials.